Privia Health Group, Inc. (NASDAQ:PRVA – Get Rating) Director William M. Sullivan sold 18,153 shares of the company’s stock in a transaction on Friday, January 20th. The stock was sold at an average price of $25.36, for a total transaction of $460,360.08. Following the completion of the transaction, the director now directly owns 5,808,777 shares of the company’s stock, valued at $147,310,584.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Privia Health Group Stock Performance
Shares of PRVA stock opened at $24.82 on Wednesday. The firm’s 50-day moving average is $23.64 and its 200-day moving average is $31.38. The stock has a market cap of $2.84 billion, a price-to-earnings ratio of -68.94 and a beta of 0.67. Privia Health Group, Inc. has a 52-week low of $17.99 and a 52-week high of $44.64.
Privia Health Group (NASDAQ:PRVA – Get Rating) last issued its earnings results on Thursday, November 10th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $342.90 million for the quarter, compared to analysts’ expectations of $323.66 million. Privia Health Group had a negative net margin of 3.02% and a negative return on equity of 6.82%. Sell-side analysts predict that Privia Health Group, Inc. will post -0.26 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on the stock. Truist Financial reduced their target price on shares of Privia Health Group to $41.00 in a research note on Thursday, November 17th. Piper Sandler cut their price target on shares of Privia Health Group to $42.00 in a research report on Thursday, November 17th. Stifel Nicolaus assumed coverage on shares of Privia Health Group in a research report on Thursday, December 8th. They set a “buy” rating and a $28.00 price target on the stock. UBS Group assumed coverage on shares of Privia Health Group in a research report on Thursday, December 8th. They set a “buy” rating and a $30.00 price target on the stock. Finally, BTIG Research cut their price target on shares of Privia Health Group from $45.00 to $40.00 in a research report on Monday, January 9th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $39.46.
Privia Health Group Company Profile
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
- Get a free copy of the StockNews.com research report on Privia Health Group (PRVA)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.